secwatch.observer — SEC 8-K summary
======================================

Issuer:     LENZ Therapeutics, Inc. (LENZ)
CIK:        0001815776
Form:       8-K
Filed at:   2024-03-22T23:59:59+00:00
Accession:  0001628280-24-012633
Event type: other_material
Sentiment:  neutral
Materiality: 1.00
Item codes: 2.01, 3.02, 4.01, 9.01, 3.03, 5.01, 5.02, 5.03, 5.05, 5.06, 7.01
LLM model:  deepseek-v4-flash:cloud@v2

Graphite Bio completes reverse merger with LENZ Therapeutics, rebrands as LENZ, raises $53.5M PIPE
--------------------------------------------------------------------------------

- Merger closed March 21, 2024; Graphite renamed LENZ Therapeutics, Inc., ticker changes from GRPH to LENZ on March 22.
- Reverse stock split 1:7 effective; post-merger shares outstanding ~25.5M, plus 164,676 warrants and 1.59M options.
- New company focuses on presbyopia treatment; Phase 3 CLARITY top-line results for LNZ100/LNZ101 expected April 2024.
- NDA submission planned mid-2024; product launch targeted for second half of 2025 if FDA approved.
- PIPE financing of $53.5M closed concurrently; audited FY2023/2022 financials of LENZ OpCo included as exhibits.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1815776/000162828024012633/0001628280-24-012633-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1815776/000162828024012633/lenz-20240321.htm
  HTML page:      https://secwatch.observer/filing/0001628280-24-012633

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer